Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
Status:
Completed
Trial end date:
2019-06-17
Target enrollment:
Participant gender:
Summary
The general objectives are to evaluate activity and the safety of regorafenib in a population
of patients bearing advanced, refractory colorectal cancers and to explore the different
downstream molecular pathways to identify tumor response and resistance mechanisms.